Trials / Completed
CompletedNCT01040234
Bilateral Dual TAP Block: Description of a Novel Four-point Approach
Ultrasound-guided Bilateral Dual Transversus Abdominis Plane (BD-TAP) Block: Description of a Novel Four-point Ultrasound-guided TAP Block Approach
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- Bispebjerg Hospital · Academic / Other
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
A prospective study of 30 patients with severe postoperative pain following abdominal surgery, in which the dual TAP block technique has been used successfully to achieve pain relief. A description of ultrasound technique, effectiveness, duration and potential side effects of the pain treatment, with possible recommendations for future use.
Detailed description
This prospective cohort study is designed to describe a novel ultrasound-guided bilateral dual transversus abdominis plane (BD-TAP) block and to evaluate the postoperative analgesic efficacy in a selection of patients having undergone major abdominal surgery under general anaesthesia where neuraxial anaesthesia and/or intravenous administration of analgesics had failed or was unwanted by the patient, or if the placement of an epidural catheter was deemed impossible by the anaesthetist in charge. 30 consecutive patients planned for the study. BD-TAP to be performed bilaterally with a high frequency linear ultrasound probe, with bupivacaine. Success rate, decline in VAS score, postoperative demand of opioids and block performance time to be recorded.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Bilateral dual TAP block | Bupivacaine 2.5 mg/ml 15 ml per injection. 4 injections per patient according to dual TAP block procedure |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2009-12-29
- Last updated
- 2015-10-23
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01040234. Inclusion in this directory is not an endorsement.